1 |
Sung PS, Shin EC. Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection. J Clin Med 2021;10:E221. [PMID: 33435135 DOI: 10.3390/jcm10020221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
2 |
Essa S, Siddique I, Saad M, Raghupathy R. Modulation of Production of Th1/Th2 Cytokines in Peripheral Blood Mononuclear Cells and Neutrophils by Hepatitis C Virus Infection in Chronically Infected Patients. Pathogens 2021;10:1519. [PMID: 34832674 DOI: 10.3390/pathogens10111519] [Reference Citation Analysis]
|
3 |
Bonilla CM, McGrath NA, Fu J, Xie C. Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus. Hepatoma Res. 2020;6. [PMID: 33134550 DOI: 10.20517/2394-5079.2020.58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
4 |
Wang X, Huang K, Jiang H, Hua L, Yu W, Ding D, Wang K, Li X, Zou Z, Jin M, Xu S. Long-Term Existence of SARS-CoV-2 in COVID-19 Patients: Host Immunity, Viral Virulence, and Transmissibility. Virol Sin 2020;35:793-802. [PMID: 33156486 DOI: 10.1007/s12250-020-00308-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
5 |
Hammad R, Eldosoky MA, Mosaad AM, El-Nasser AM, Kotb FM, Elshennawy SI, Eldesoky NA, Selim MA, Naguib GG, Ahmed OA, Alboraie M, Aglan RB. Natural Killer Group 2D Receptor and B1a Cells Crosstalk in Post-Hepatitis C Virus Infection Hepatocellular Carcinoma and Cirrhosis. J Hepatocell Carcinoma 2022;9:609-19. [PMID: 35879974 DOI: 10.2147/JHC.S360886] [Reference Citation Analysis]
|
6 |
Leslie J, Geh D, Elsharkawy AM, Mann DA, Vacca M. Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|